Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort study

Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort study

Background Single-agent PD-(L)1 blockade (IO) alone or in combination with chemotherapy (Chemotherapy-IO) is approved first-line therapies in patients with advanced lung adenocarcinomas (LUADs) with PD-L1 expression ≥1%. These regimens have not been compared prospectively. The primary objective was...

Full description

Bibliographic Details
Main Authors: Yuan Chen, Biagio Ricciuti, Matthew D Hellmann, Hira Rizvi, Mark M Awad, Giuseppe Lamberti, Arielle Elkrief, Jamie E Chaft, Xinan Wang, Samantha Brown, Charles M Rudin, Joao M Victor Alessi, Isabel R Preeshagul, Federica Pecci, Alessandro Di Federico, Jacklynn V Egger, Gregory J Riely, Mark G Kris, Marc Ladanyi, Ronglai Shen, Adam J Schoenfeld
Format: Article
Language:English
Published: BMJ Publishing Group 2023-07-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/11/7/e006994.full

Internet

https://jitc.bmj.com/content/11/7/e006994.full

Similar Items